Douglas B. Kirsch
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Douglas B. Kirsch.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2015
Nathaniel F. Watson; Timothy I. Morgenthaler; Ronald D. Chervin; Kelly A. Carden; Douglas B. Kirsch; David A. Kristo; Raman K. Malhotra; Jennifer L. Martin; Kannan Ramar; Ilene M. Rosen; Terri E. Weaver; Merrill S. Wise
ABSTRACT Drowsy driving is a serious public health concern which is often difficult for individual drivers to identify. While it is important for drivers to understand the causes of drowsy driving, there is still insufficient scientific knowledge and public education to prevent drowsy driving. As a result, the AASM is calling upon institutions and policy makers to increase public awareness and improve education on the issue, so our society can better recognize and prevent drowsy driving. The AASM has adopted a position statement to educate both healthcare providers and the general public about drowsy driving risks and countermeasures.
Journal of Clinical Sleep Medicine | 2015
Nathaniel F. Watson; Timothy I. Morgenthaler; Ronald D. Chervin; Kelly A. Carden; Douglas B. Kirsch; David A. Kristo; Raman K. Malhotra; Jennifer L. Martin; Kannan Ramar; Ilene M. Rosen; Terri E. Weaver; Merrill S. Wise
ABSTRACT Drowsy driving is a serious public health concern which is often difficult for individual drivers to identify. While it is important for drivers to understand the causes of drowsy driving, there is still insufficient scientific knowledge and public education to prevent drowsy driving. As a result, the AASM is calling upon institutions and policy makers to increase public awareness and improve education on the issue, so our society can better recognize and prevent drowsy driving. The AASM has adopted a position statement to educate both healthcare providers and the general public about drowsy driving risks and countermeasures.
Journal of Clinical Sleep Medicine | 2017
Nathaniel F. Watson; Jennifer L. Martin; Merrill S. Wise; Kelly A. Carden; Douglas B. Kirsch; David A. Kristo; Raman K. Malhotra; Eric J. Olson; Kannan Ramar; Ilene M. Rosen; James A. Rowley; Terri E. Weaver; Ronald D. Chervin
ABSTRACT During adolescence, internal circadian rhythms and biological sleep drive change to result in later sleep and wake times. As a result of these changes, early middle school and high school start times curtail sleep, hamper a students preparedness to learn, negatively impact physical and mental health, and impair driving safety. Furthermore, a growing body of evidence shows that delaying school start times positively impacts student achievement, health, and safety. Public awareness of the hazards of early school start times and the benefits of later start times are largely unappreciated. As a result, the American Academy of Sleep Medicine is calling on communities, school boards, and educational institutions to implement start times of 8:30 AM or later for middle schools and high schools to ensure that every student arrives at school healthy, awake, alert, and ready to learn.
Journal of Clinical Sleep Medicine | 2018
Kannan Ramar; Ilene M. Rosen; Douglas B. Kirsch; Ronald D. Chervin; Kelly A. Carden; R. Nisha Aurora; David A. Kristo; Raman K. Malhotra; Jennifer L. Martin; Eric J. Olson; Carol L. Rosen; James A. Rowley
ABSTRACT The diagnosis and effective treatment of obstructive sleep apnea (OSA) in adults is an urgent health priority. Positive airway pressure (PAP) therapy remains the most effective treatment for OSA, although other treatment options continue to be explored. Limited evidence citing small pilot or proof of concept studies suggest that the synthetic medical cannabis extract dronabinol may improve respiratory stability and provide benefit to treat OSA. However, side effects such as somnolence related to treatment were reported in most patients, and the long-term effects on other sleep quality measures, tolerability, and safety are still unknown. Dronabinol is not approved by the United States Food and Drug Administration (FDA) for treatment of OSA, and medical cannabis and synthetic extracts other than dronabinol have not been studied in patients with OSA. The composition of cannabinoids within medical cannabis varies significantly and is not regulated. Synthetic medical cannabis may have differential effects, with variable efficacy and side effects in the treatment of OSA. Therefore, it is the position of the American Academy of Sleep Medicine (AASM) that medical cannabis and/or its synthetic extracts should not be used for the treatment of OSA due to unreliable delivery methods and insufficient evidence of effectiveness, tolerability, and safety. OSA should be excluded from the list of chronic medical conditions for state medical cannabis programs, and patients with OSA should discuss their treatment options with a licensed medical provider at an accredited sleep facility. Further research is needed to understand the functionality of medical cannabis extracts before recommending them as a treatment for OSA.
Handbook of Clinical Neurology | 2011
Douglas B. Kirsch; Ronald D. Chervin
Publisher Summary Excessive daytime sleepiness (EDS) is a common symptom of insufficient sleep, inadequate sleep, intrinsic sleep disorders, and many other medical conditions. Patients who suffer from EDS are common in the practices of primary care physicians, many types of specialists, and particularly sleep medicine specialists. To provide an appropriate diagnosis and effective treatment options, careful assessment by history, physical examination, and other approaches is often necessary. Repeated assessments may be necessary to track changes in EDS and response to treatment over time. A National Sleep Foundation poll in 2002 suggested that 37% of adults are so sleepy during the day that it interferes with their daily activities a few days a month or more; 16% experience this level of daytime sleepiness a few days a week or more. It was found that 51%percent of the polled subjects reported driving while drowsy and 17% have dozed off while driving. Increased subjective daytime somnolence and chronically disrupted sleep also have been associated with an increase in estimated healthcare use. Findings demonstrated that sleep attacks and irresistible sleepiness were more specific and sensitive for short mean sleep latencies on formal testing than tiredness or resistible sleepiness.
Journal of Clinical Sleep Medicine | 2018
Seema Khosla; Maryann C. Deak; Dominic Gault; Cathy A. Goldstein; Dennis Hwang; Younghoon Kwon; Daniel O'Hearn; S Schutte-Rodin; Michael Yurcheshen; Ilene M. Rosen; Douglas B. Kirsch; Ronald D. Chervin; Kelly A. Carden; Kannan Ramar; R. Nisha Aurora; David A. Kristo; Raman K. Malhotra; Jennifer L. Martin; Eric J. Olson; Carol L. Rosen; James A. Rowley
ABSTRACT Consumer sleep technologies (CSTs) are widespread applications and devices that purport to measure and even improve sleep. Sleep clinicians may frequently encounter CST in practice and, despite lack of validation against gold standard polysomnography, familiarity with these devices has become a patient expectation. This American Academy of Sleep Medicine position statement details the disadvantages and potential benefits of CSTs and provides guidance when approaching patient-generated health data from CSTs in a clinical setting. Given the lack of validation and United States Food and Drug Administration (FDA) clearance, CSTs cannot be utilized for the diagnosis and/or treatment of sleep disorders at this time. However, CSTs may be utilized to enhance the patient-clinician interaction when presented in the context of an appropriate clinical evaluation. The ubiquitous nature of CSTs may further sleep research and practice. However, future validation, access to raw data and algorithms, and FDA oversight are needed.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2013
Douglas B. Kirsch
Journal of Clinical Sleep Medicine | 2017
Ilene M. Rosen; Douglas B. Kirsch; Ronald D. Chervin; Kelly A. Carden; Kannan Ramar; R. Nisha Aurora; David A. Kristo; Raman K. Malhotra; Jennifer L. Martin; Eric J. Olson; Carol L. Rosen; James A. Rowley
Sleep Medicine | 2005
Douglas B. Kirsch; Alon Y. Avidan
/data/revues/02725231/v35i3/S0272523114000471/ | 2014
Maryann Deak; Douglas B. Kirsch